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Abstract
WHIM (warts, hypogammaglobulinemia, infections, and myelokatexis) syndrome is a rare immunodeficiency syndrome
linked to heterozygous mutations of the chemokine receptor CXCR4 resulting in truncations of its cytoplasmic tail.
Leukocytes from patients with WHIM syndrome display impaired CXCR4 internalization and enhanced chemotaxis in
response to its unique ligand SDF-1/CXCL12, which likely contribute to the clinical manifestations. Here, we investigated the
biochemical mechanisms underlying CXCR4 deficiency in WHIM syndrome. We report that after ligand activation, WHIM-
associated mutant CXCR4 receptors lacking the carboxy-terminal 19 residues internalize and activate Erk 1/2 slower than
wild-type (WT) receptors, while utilizing the same trafficking endocytic pathway. Recruitment of b-Arrestin 2, but not b-
Arrestin 1, to the active WHIM-mutant receptor is delayed compared to the WT CXCR4 receptor. In addition, while both
kinases Grk3 and Grk6 bind to WT CXCR4 and are critical to its trafficking to the lysosomes, Grk6 fails to associate with the
WHIM-mutant receptor whereas Grk3 associates normally. Since b-Arrestins and Grks play critical roles in phosphorylation
and internalization of agonist-activated G protein-coupled receptors, these results provide a molecular basis for CXCR4
dysfunction in WHIM syndrome.
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Introduction
The G protein-coupled receptor CXCR4 and its chemokine
ligand stromal cell-derived factor-1 (SDF-1, also termed CXCL12)
play essential roles in the development and function of the
hematopoietic system [1–4]. SDF-1/CXCL12 is constitutively
expressed in various adult tissues, including bone marrow, lung,
liver, lymph nodes, and skin [5,6]. In the bone marrow, stromal cells,
osteoblasts and endothelial cells are the source of SDF-1/CXCL12
[7-9],andcontributetodistincthematopoieticstemcellnichesinpart
through the production of SDF-1/CXCL12 [10–14]. Bone marrow
myeloid and lymphoid cells express a functional CXCR4.
Homeostatic levels of peripheral blood neutrophils increase
during bacterial infections and other forms of stress, and this rise is
principally regulated through their dynamic release from the bone
marrow to the circulation [15]. Although the biochemical
mechanisms underlying this process are incompletely defined,
there is compelling evidence that SDF-1/CXCL12 stimulation of
CXCR4 is a principal regulator for retention and stress-induced
mobilization of myeloid lineage cells from the bone marrow to the
blood [16–18].
WHIM syndrome is a rare immunodeficiency disorder
characterized by papillomavirus-induced warts, hypogammaglob-
ulinemia, recurrent bacterial infection, and myelokathexis, a type
of neutropenia associated with the retention and death of mature
neutrophils in the bone marrow [19–21]. The majority of patients
with WHIM syndrome have been linked to heterozygous genetic
mutations in the gene encoding CXCR4 resulting in truncations of
the cytosolic carboxy-terminal portion of the receptor and thus co-
express the normal and mutant CXCR4 proteins [22,23]. The
most extensive WHIM-associated truncation removes nineteen
amino acids from the carboxy-terminus of CXCR4 whereas the
least extensive truncation removes only ten amino acids from
the carboxy-terminus [21,22]. Functionally, WHIM-associated
CXCR4 mutants display enhanced and prolonged responses to
SDF-1/CXCL12, and this CXCR4 gain of function is believed to
contribute to increased neutrophil retention to the bone marrow,
their reduced release to the peripheral circulation leading to
senescence and apoptotic death within the bone marrow
[20,22,23]. G-CSF, which downregulates expression of the
CXCR4 receptor and its ligand SDF-1/CXCL12 [24–26], is
commonly used to reduce neutropenia in WHIM patients.
A number of studies have investigated the physiologic mechanisms
of CXCL12/CXCR4 signaling [23,27,28]. In brief, upon ligand
binding, CXCR4 becomes phosphorylated on several serine and
threonine residues in the cytoplasmic carboxy-terminal tail, recruits a
b-Arrestin, which leads to clathrin dependent CXCR4 internaliza-
tion, ubiquitination, and eventual lysosomal degradation. In spite of
general agreement on the sequence of events accompanying CXCR4
signaling and degradation, many questions persist on the biochemical
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CXCR4 mutants, it is unclear which step or steps are abnormal.
Biochemical studies with WHIM-CXCR4 mutants detected im-
paired ligand-mediated internalization and calcium ion mobilization
in some studies [22,29], but not others [30]. Signaling dysfunction
reflected by altered Erk 1/2 phosphorylation was noted in ligand-
activated WHIM leukocytes expressing wild-type (WT) and mutant
CXCR4, and was attributed to a transdominant-negative effect of the
mutant CXCR4 over the WT CXCR4 [28,29]. A contribution of b-
Arrestin2 to defective signaling by mutant CXCR4 was suggested by
some studies [31]. In addition, altered cell response to SDF1/
CXCL12 in mutant mice lacking the G protein-coupled receptor
kinase, GRK6, and the discovery of WHIM patients having GRK3
defects and no CXCR4 mutation suggested a contribution of GRKs
to signaling defects of CXCR4 mutant receptors [32–34].
In the current study, we demonstrate that the WHIM-associated
mutant CXCR4 is defective at recruiting b-Arrestin 2 and GRK6
proteins after exposure to the ligand, and displays a delay in
ligand-induced internalization, signaling and trafficking in com-
parison to WT CXCR4.
Results
Receptor Internalization of WT and Mutant CXCR4
To define the molecular basis for WHIM syndrome, we
generated HeLa cell lines that stably expressed either wild-type
(WT) CXCR4 or a mutant CXCR4 with a 19 amino acid
truncation at the carboxy-terminus. This is the most extensive
CXCR4 truncation associated with WHIM syndrome [20–22,30],
which derived from a frame shift mutation (previously designated
WHIM R334X, Figure 1A). Earlier studies have shown that Green
Fluorescent Protein (GFP) fusions to the N-terminus of CXCR4 do
not disrupt CXCL12/SDF1 ligand binding or receptor function
[35]. Therefore, we produced WT and mutant CXCR4 proteins
tagged with an N-terminal fusion protein of GFP, which allows
visualization of the transfected proteins and distinguishes them from
the endogenous protein that is expressed in HeLa cells.
Using antibodies against GFP, Western blot analysis revealed
that HeLa cells expressed similar levels of GFP-WT or GFP-
WHIM mutant CXCR4 proteins, which displayed their predicted
relative molecular weights from the fusion with GFP (Figure 1B).
The endogenous CXCR4 (relative size 44–47kDa) was visualized
only after prolonged exposure, and was estimated to represent
,15–20% of the total CXCR4 receptor in the trasnfected cells
(data not shown). To establish the identity of the bands recognized
by direct Western blotting with anti-GFP antibodies, we used
antibodies against GFP to immunoprecipitate the tagged proteins
from total cell lysates followed by immunoblotting with antibodies
against CXCR4 (Figure 1B). Using FACS analysis, we determined
that the percentage of cells expressing GFP-CXCR4 was 67–90%
for both constructs and was maintained at this level under selective
pressure (Figure 1C, representative results).
Figure 1. Transduction and stable expression of WT and mutant forms of CXCR4 in HeLa cells. A, amino acid sequence of the C-terminal
tails of WT CXCR4 and the mutant form of CXCR4 (WHIM R334X) utilized in the current study. B, HeLa cells stably transduced with GFP-WT CXCR4 or
GFP-WHIM were lysed and analyzed by SDS-PAGE and Western blotting using anti-GFP antibodies or immunoprecipitated with anti-GFP antibody
and immunoblotted with anti-CXCR4 antibody. Accuracy of loading was assessed by reprobing the membrane with anti-actin antibodies. C, flow
cytometric analysis of GFP expression in control (non-transduced, NT) Hela cells and HeLa cells stably transduced with GFP-CXCR4 (WT and WHIM).
doi:10.1371/journal.pone.0008102.g001
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CXCR4 internalization in cells from patients with WHIM
syndrome [28], we tested whether HeLa cells expressing the
WHIM-associated CXCR4 mutant show a similar impairment.
Using flow cytometry to measure the rate of CXCL12/SDF1-
induced CXCR4 internalization, we found that WHIM mutant
CXCR4 receptors show a slower rate of ligand-induced
internalization compared to WT receptor (Figure 2A and B). At
the 80 minutes time-point, the WHIM mutant CXCR4 receptor
showed a reduction in the mean internalization compared to the
WT receptor (Figure 2C), which was significant (P=0.036). These
quantitative differences in receptor internalization were observed
over a wide range of ligand concentrations (10–100 ng/ml, not
shown), consistent with cells expressing similar levels of WT or
mutant receptors (Figure 1C and Figure 2A, B green line) and with
the use of saturating amounts of ligand.
Receptor Internalization Defects Lead to Delayed MAP
Kinase Signaling
CXCR4 can signal through the MAP kinase and Akt pathways
[36,37]. We tested whether ligand-induced signaling from the
WHIM mutant CXCR4 receptor is altered compared to that from
the WT receptor. Consistent with the results in figures 1 and 2
showing delayed WHIM receptor internalization compared to
WT, we found that ligand- induced Erk 1/2, but not Akt,
phosphorylation was delayed in HeLa cells expressing the WHIM
mutant CXCR4 compared to HeLa cells expressing the WT
receptor (Figure 2D). This result is consistent with Lagane et al.
Figure 2. Ligand-induced internalization of WT and WHIM CXCR4 examined by flow cytometry and confocal microscopy. A–C, HeLa
cells stably expressing GFP-WT CXCR4 or GFP-WHIM CXCR4 constructs were exposed to 25 ng/ml SDF-1/CXCL12 for 0, 40 or 80 min at 37uC and then
stained for cell surface CXCR4 using antibodies to GFP to detect the transduced CXCR4 and distinguish it from the endogenous protein; levels of cell
surface GFP-CXCR4 were measured by flow cytometry. The red line depicts results from control staining with isotype control immunoglobulin and
secondary antibody. Results in A and B reflect a representative experiment showing CXCR4 mean fluorescence intensities at the indicated time-
points; results in C reflect the mean (6SD) levels of cell surface CXCR4 (measured by mean fluorescence intensity, MFI) at the 80 min time-point from
3 independent experiments; the results are expressed as a percentage of receptor levels (as measured by MFI) found on the surface at time 0 (0 min).
D, Hela cells stably expressing GFP-WT CXCR4 or GFP-WHIM CXCR4 were exposed to SDF-1/CXCL12 (25 ng/ml) for the indicated time intervals; cell
lysates were separated by SDS-PAGE and analyzed by Western blotting using specific antibodies to phosphorylated Akt and Erk 1/2; for loading
controls, membranes were re-probed with antibodies to total Erk 1/2. E, HEK 293 cells were transiently transfected with WT, WHIM, or both receptors;
HeLa cells were transiently transfected with both WT and WHIM receptors. Transfected cells were exposed to SDF-1/CXCL12 (25 ng/ml) for the
indicated times and cell lysates analyzed by SDS-PAGE and Western blotting. F, Huvec were plated in monolayers onto 96-well plates, and were
activated overnight with 2 ng/ml of TNFa. CFSE-labeled KG1a cells expressing, WT or WHIM CXCR4 were incubated at 5610
4 cells per well onto
TNFa2preactivated Huvec monolayers in triplicate for 30 min. After removal of non-adherent cells, adherent cells were counted by reading
fluorescence at ,520 nm. The results reflect the mean +/2 SD of triplicate wells in a representative experiment performed three times.
doi:10.1371/journal.pone.0008102.g002
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[31]. While Erk 1/2 activation by the WT receptor was maximal
at 5–15 min, Erk 1/2 activation by the WHIM mutant was
maximal at 30–60 min. As a consequence of this difference in
kinetics, signaling by a cell consisting of both a WT and a mutant
receptor at a 1:1 ratio would be expected to have a signaling time
that would be extended. Such a prediction is consistent with
previous reports showing extended Erk 1/2 signaling from WHIM
patient cells [31].
To test directly this prediction, we transiently transfected WT
and WHIM CXCR4 individually or together in HEK 293 cells
and examined the kinetics of Erk 1/2 signaling in response to
SDF-1/CXCL12. We selected HEK 293 cells for these experi-
ments because they do not express endogenous CXCR4. As shown
in Figure 2E, Erk 1/2 signaling was maximal at 15 minutes in cells
expressing the WT receptor, whereas it was only detected at 60
minutes in cells expressing the WHIM receptor. When both WT
and WHIM receptors were co-expressed in HEK 293 cells,
signaling had a bimodal pattern with a peak at 15 minutes and a
second peak at 60 minutes, likely reflective of signaling by the
individual receptors. These results support our prediction, and are
consistent with the extended signaling observed in patients with
WHIM. To confirm that such a bimodal pattern was not unique to
HEK 293 cells, we transiently transfected equal amounts of both
receptors into HeLa cells. Although the kinetics of signaling were
slightly different from those with HEK 293 cells, the bimodal
pattern of Erk1/2 signaling was also observed (Figure 2E),
providing additional evidence for the presence of prolonged
signaling when WT and WHIM receptors are expressed.
We also compared WT and WHIM CXCR4 in attachment
assays. We used monolayers of human umbilical vein endotehlial
cells (Huvec) as a source of SDF1 bound to cell surface
proteoglycans [38]. Since Hela cells attach poorly to Huvec, we
transduced the myeloid KG1a (that do not express detectable
levels of endogenous CXCR4) with WT and WHIM CXCR4. In
experiments not shown, we established that KG1a expressed
similar levels of WT and WHIM CXCR4, and that WHIM
CXCR4 expressing KG1a displayed a delay in SDF1 induced
CXCR4 internalization. As shown in Figure 2E, myeloid cells
expressing WHIM CXCR4 displayed a significantly (P,0.05)
enhanced attachment to activated Huvec compared to WT
control.
The defect in ligand-induced internalization exhibited by the
WHIM mutant receptor could also be visualized by immunoflu-
orescence using confocal microscopy. We incubated the cells at
4uC with anti-GFP antibodies to distinguish the transfected
receptor on the cell surface from the receptor contained within
internal organelles. After washing, the cells were incubated with
labeled transferrin and either fixed or incubated at 37uC for the
times indicated in the presence of the ligand (10 ng/ml) to induce
receptor internalization, and then washed and fixed. We observed
a clear difference between cells expressing the WHIM mutant and
WT receptor in the degree of ligand-induced CXCR4 internal-
ization. After 90 minutes incubation, most of the WHIM mutant
was detected on or close to the cell surface membrane (Figure 3A,
white arrows), whereas most of the WT receptor was detected
inside the cells (Figure 3A, white arrows). At time 0, both WT and
mutant receptors were detected on or close to the cell surface
membrane (Figure 3A, white arrows).
A possible explanation for the kinetic difference in receptor
internalization is that the WT and mutant receptors use a different
pathway for internalization. It was previously shown that CXCR4
uses a clathrin-dependent pathway to reach early endosomes
[39,40].Weused immunofluorescencetoexamine co-localization of
the WT and WHIM mutant receptors with the endosomal markers:
Rab5, Rab7 and Rab11 [40]. As can be seen in figure 3B, there was
nodiscernibledifferenceintrafficking patternsbetween the WTand
mutant receptor as both receptors colocalized with the three
endosomal markers. These results provide evidence for a common
trafficking pathway of the WT and WHIM mutant receptors.
Recruitment of b-Arrestin 2 but Not b-Arrestin 1 Is
Delayed to the WHIM CXCR4 Receptor
Earlier studies have demonstrated that ligand-activated CXCR4
binds b-Arrestin 2 (also known as Arrestin 3), a process that
facilitates receptor internalization [27,41]. Recently, a GFP-tagged
b-Arrestin 2 was reported to physically interact with the WT and a
WHIM-associated CXCR4 mutant receptor (CXCR4
1013), pro-
viding evidence that a 15-residue C-terminal truncation of
CXCR4 does not prevent b-Arrestin 2 binding to the receptor
[31]. In addition, since b-Arrestin 2 silencing normalized the
extended ligand-induced Erk 1/2 activation by this
CXCR4
1013mutant receptor, b-Arrestin 2 was implicated in this
defective response [31]. To further evaluate the potential role of b-
Arrestin 2 in the kinetic abnormalities of ligand-induced WHIM
mutant CXCR4 activation, we transfected HeLa cells (parental,
WT GFP-CXCR4 and WHIM GFP-CXCR4, which lacks the 19
C-terminal residues) with a FLAG-tagged construct of b-Arrestin
2. First, we examined whether the FLAG-b-Arrestin 2 could
associate with WT and WHIM CXCR4. After stimulating the
HeLa cells for 10 min with CXCL12/SDF-1, immunoprecipitat-
ing CXCR4 (anti-GFP antibody) and re-blotting for b-Arrestin 2
(anti-FLAG antibody), we detected b-Arrestin 2 (barr2) in
immunoprecipitates from HeLa cells transduced with the WT
receptor, but not from HeLa cells transduced with the WHIM
mutant receptor (Figure 4A). This reproducible difference could
not be attributed to reduced immunoprecipitation of WHIM
mutant CXCR4 compared to the WT receptor from HeLa cells
(Figure 4A). The immunoprecitation was specific, as GFP-CXCR4
was not detected in cell lysates from the parental, non-transduced
(NT) Hela cells (Figure 4A).
This result was unexpected because Lagane et al. reported that a
WHIM mutant receptor with a similar C-terminal truncation (15
residues compared to 19 residues used here) associated with b-
Arrestin 2 [31]. Since Lagane et al. reported examining one time
point only, which was not described [31], we evaluated whether this
difference might be attributable to a kinetic difference. To test for
this possibility, we exposed HeLa cells to SDF-1/CXCL12 for
different intervals, immunoprecipitated CXCR4 by using an anti-
GFP antibody and probed the immunoprecipitates with an
antibody to b-Arrestin 2. In the absence of ligand, no FLAG-b-
Arrestin 2 could be immunoprecipitated from Hela cells expressing
WT or WHIM mutant CXCR4 (Figure 4B). Upon addition of
SDF-1/CXCL12 for 5, 10 and 30 minutes, the WT and mutant
receptors showed kinetic differences in their ability to associate with
b-Arrestin 2, as judged by co-precipitation: at 5 and 10 minutes, the
WT CXCR4 was complexed with b-Arrestin 2, but the mutant
CXCR4 was minimally associated (Figure 4B). Only after 30
minutes exposure to the ligand, did we detect the mutant CXCR4
in a complex with b-Arrestin 2 (Figure 4B). While confirming the
earlier observation that mutant CXCR4 can associate with b-
Arrestin 2, the current biochemical data uncovered kinetic
differences in the recruitment of b-Arrestin 2 by the WT and
WHIM mutant CXCR4. Such kinetic difference is consistent with
the results (Figures 1 and 2) showing that the mutant receptor is
slower at leaving the plasma membrane in the presence of ligand.
We confirmed these results by immunofluorescence staining and
confocal microscopy. CXCR4-expressing (WT or WHIM mutant)
Grk6 and b-Arrestin2 in WHIM
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Arrestin 2 construct, and 3 days later the cells were incubated for
10 minutes with CXCL12/SDF-1. In the case of cells expressing
WT-CXCR4, b-Arrestin 2 (Barr2) could to be seen in punctate
structures that colocalized at least in part with the receptor
(Figure 4C, representative images of 10 fields examined). By
contrast, in the case of cells expressing the WHIM mutant
receptor, b-Arrestin 2 was not detected in such structures after 10
minutes exposure to the ligand, and the mutant receptor was
mostly confined to the cell surface (Figure 4C, representative
images of 10 fields examined).
The proteins b-Arrestin-2 (also known as Arrestin-3) and b-
Arrestin-1 (also known as Arrestin 2) share a 78% identity at the
amino acid level, and have both been shown to play a role in the
internalization of various seven-membrane spanning receptors,
including CXCR4 [42]. Therefore, we examined whether the
delayed recruitment of b-Arrestin 2 by the mutant WHIM
CXCR4 receptor was accompanied by a delay in the recruitment
of b-Arrestin 1. In co-immunoprecipitation experiments, we found
that b-Arrestin-1 similarly associated with the WT and WHIM
mutant CXCR4 receptors after 10 and 30 minutes activation by
the ligand (Figure 4D). These experiments provide evidence that
delayed binding to WHIM-mutant CXCR4 is a characteristic of
b-Arrestin 2, but not b-Arrestin 1.
Grk6 and Grk3 Associate with CXCR4
G protein-coupled receptor kinases (Grks) phosphorylate ligand-
activated G protein-coupled receptors on serine and threonine
residues within the carboxy-terminal tail and intracellular loops, a
process that is accompanied by the recruitment of b-Arrestins [27].
Among the seven known Grks [41], there is circumstantial evidence
that Grk6 and Grk3, but not other Grks, may participate in WHIM-
associated defective CXCR4 internalization. In Grk6-deficient mice,
the neutrophils display enhanced SDF-1/CXCL12-induced chemo-
taxisinvitro,andthus displaysomeofthe hematological abnormalities
of patients with WHIM syndrome [33,43]. In addition, Grk3 was
shown to complex with CXCR4 [44]. Recently, a patient with
WHIM syndrome who did not have a mutant CXCR4 (WHIM
WT)
was reported to have a selective decrease in GRK3 expression levels
[32]. Thus, Grk3 deficiency has been associated with WHIM
syndrome [32]. Despite these important findings, the role of Grk3
and Grk6 in physiological CXCR4 internalization and WHIM-
mutant CXCR4 dysfunction is still unclear.
To identify whether Grk3 or Grk6 might be involved in the
CXCR4 responses to SDF-1/CXCL12, we first examined
expression of Grk3 and Grk6. By Western blotting, we detected
similar levels of Grk3 and Grk6 in HeLa cells stably expressing
GFP-WT or GFP-mutant CXCR4 (Figure S1). We then performed
co-immunoprecipitation experiments in the presence or absence of
Figure 3. Analysis of trafficking pathways utilized by WT and WHIM mutant CXCR4. A, HeLa cells stably expressing GFP-WT CXCR4 or GFP-
WHIM CXCR4 were incubated at 37uC with SDF-1/CXCL12 (25 ng/ml) for 0, 5, 30 and 90 min in the presence of labeled (Alexa 568) transferrin and
anti-GFP antibodies. The cells were fixed, immunostained with anti-GFP antibodies and examined by confocal microscopy. Representative images
depicting the distribution of internalized CXCR4 (green), internalized transferrin (red) and colocalization of internalized CXCR4 and transferrin (yellow).
The white arrows highlight the different degree of receptor internalization by the WT and the WHIM CXCR4 at time 0 and 90 min. B, HeLa cells stably
expressing GFP-WT CXCR4 or GFP-WHIM CXCR4 were transfected with plasmids encoding Rab11-DsRed2, Rab5-RFP, or Rab7-RFP, incubated at 37uC
overnight, fixed and mounted.
doi:10.1371/journal.pone.0008102.g003
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ies to GFP to immunoprecipitate CXCR4 from HeLa cells stably
expressing GFP-WT or GFP-mutant CXCR4, and probed the
precipitates with antibodies to Grk6 and Grk3. We found both
kinases to be associated with ligand-activated WT CXCR4
(Figure 5A and B). When the WHIM mutant CXCR4 was used
in the co-immunoprecipitation assays, we found no receptor
association with Grk6 (Figure 5A). By contrast, the ligand-activated
WHIM mutant CXCR4 and the WT receptors bound similarly to
Grk3 (Figure 5B). This observation was confirmed in 3 separate
experiments (Figure 5C). These results suggest that the C-terminal
19 residues of CXCR4 are important for the interaction with Grk6
but not Grk3, and provide evidence that Grk3 and Grk6 may not
require the same CXCR4 structural elements for interaction.
Silencing Grk6 and Grk3 Impairs CXCR4 Trafficking
Depletion of b-Arrestin 1 was reported to cause CXCR4
trapping in early endosomes, which was attributed to defective
recruitment of the ubiquitin ligase AIP4 (atrophin1 interacting
protein 4) [39]. If Grk3 and Grk6 play a role in recruiting the b-
Arrestins to the CXCR4 receptor, as previously suggested [27],
then silencing the two kinases should provide a similar phenotype
to that derived from silencing b-Arrestin 1. To test for this
possibility, we examined the effects of silencing Grk3 or Grk6 in
HeLa cells on ligand-induced CXCR4 receptor internalization.
Using siRNA oligos, we substantially depleted the cells of Grk3 or
Grk6 (Figure 5D and E). By immunofluorescence, we observed
(Figure 5F) significant CXCR4 receptor (marked by GFP)
internalization in control-treated HeLa cells. By contrast, when
HeLa cells were depleted of either Grk3 or Grk6 we observed
CXCR4 receptor staying at or close to the plasma membrane.
These results provide evidence for a role for both Grk3 and Grk6
in CXCR4 trafficking.
Grk6 Can Influence CXCR4 Signaling
Lefkowtiz and colleagues [45] have shown that b-Arrestin 2 can
serve as a scaffolding protein for signaling molecules while Lagane
et al. [31] and others have shown that b-Arrestin 2 is important for
Erk 1/2 signaling through CXCR4. If Grk6 is important for b-
Arrestin 2 recruitment to CXCR4 then silencing Grk6 should alter
Figure 4. Analysis of WT-CXCR4 and WHIM-CXCR4 interaction with b-Arrestin 2. A, Non transduced (NT) Hela cells, or HeLa cells stably
expressing GFP-WT CXCR4 or GFP-WHIM CXCR4 were transiently transfected with a FLAG-tagged b-Arrestin 2 construct; 48 hours after transfection,
the cells were incubated at 37uC with SDF-1/CXCL12 (25 ng/ml) for 10 min; cell lysates were immunoprecipitated with anti-GFP antibodies to detect
transduced CXCR4; the immunoprecipitates were separated through SDS-PAGE and analyzed by Western blotting. The results reflect immunoblotting
with anti-FLAG antibodies to detect b-Arrestin 2 and reprobing with antibodies to GFP to detect the immunoprecipitated GFP-CXCR4 (representative
from 5 experiments). B, The experiment was performed as in (A), except that the HeLa cells were exposed to SDF-1/CXCL12 for 5, 10 and 30 min prior
to lysis. C, HeLa cells stably expressing GFP-WT CXCR4 or GFP-WHIM CXCR4 were transiently transfected with FLAG-tagged b-Arrestin 2, incubated
with 25 ng/ml SDF-1/CXCL12 for 10 min or 30 min at 37uC, fixed and then stained with anti-FLAG antibody to detect b-Arrestin 2 (Barr2, red). GFP
fluorescence (green) denotes the transduced CXCR4; colocalization of b-Arrestin 2 and CXCR4 is in yellow. Each of the images shown is representative
of 10 fields examined. The experiment is representative of 3 independent experiments performed. D, Hela cells stably expressing GFP-WT CXCR4 or
GFP-WHIM CXCR4 were either mock transfected (NT) or were transfected with a FLAG-b-Arrestin 1 construct; after 48 hours the cells were exposed to
SDF-1/CXCL12 (25 ng/ml, 37uC, 10 and 30 min) and the cell lysates were immunoprecipitated with anti-GFP antibodies. Immunoprecipitates and
aliquots of cell lysates used for the IP were separated onto SDS-PAGE and immunoblotted with anti-FLAG antibodies to detect b-Arrestin 1.
doi:10.1371/journal.pone.0008102.g004
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1/2 signaling in Grk6-silenced and control Hela cells expressing
WT-CXCR4. As shown in Figure 5G, Grk6 depletion led to a
delay of pErk 1/2 activation by SDF1, which was similar to that
seen in Hela cells expressing the WHIM-CXCR4 receptor
(compare with Figure 2D). This is further evidence that Grk6 is
important in CXCR4 function.
Discussion
In the current study, we have dissected the early events that
follow ligand binding to the CXCR4 receptor to identify
deficiencies stemming from a mutant CXCR4, which is missing
the 19 carboxy-terminal residues and is associated with WHIM
syndrome. Five important observations were made. First, the
mutant receptor is internalized later than the WT receptor after
ligand binding. Second, the mutant and WT receptors use the
same protein trafficking pathway marked by Rab 5, 7, and 11.
Third, ligand-induced phosphorylation of Erk 1/2 is delayed in
cells bearing the mutant receptors. Thus, the presence of both a
WT and WHIM mutant allele would be expected to result in
prolonged Erk 1/2 activation stemming from the combined effect
of WT and mutant receptor. Fourth, b-Arrestin 2 recruitment to
the activated mutant receptor is delayed compared to the WT
receptor, whereas b-Arrestin 1 is not. Fifth, Grk3 and Grk6 bind to
the active WT receptor and both are important for its trafficking.
However, Grk6 fails to physically associate with the ligand-
activated mutant receptor.
Figure 5. CXCR4 interaction with Grk3 and GRK6. A, HeLa cells expressing GFP-CXCR4 (WT or WHIM mutant) were incubated with SDF-1/
CXCL12 (25 ng/ml, 37uC, 30 min); cell lysates were immunoprecipitated with anti-GFP antibodies to immunoprecipitate GFP-CXCR4; the
immunoprecipitates were separated by SDS-PAGE and immunoblotted with an antibody to Grk6. The blots were re-probed with anti-GFP antibodies
to detect transduced CXCR4. B and C, Hela cells expressing GFP-CXCR4 (WT and WHIM) constructs were incubated with SDF-1/CXCL12 (25 ng/ml,
37uC, 30 min) immunoprecipitated with anti-GFP antibody to pull down transduced CXCR4, probed for Grk3, and reprobed for CXCR4 with anti-
CXCR4 antibodies. Representative results are shown in B; average ratio (6SD) of Grk3 and CXCR4 band intensity in 3 separate immunoprecipitation
experiments shown in C. D and E, levels of Grk6 (D) or Grk3 (E) in HeLa cells expressing GFP-WT CXCR4 after 3-day treatment with control or specific
siRNAs detected by immunoblotting with antibodies to Grk3 or Grk6. The membranes were reprobed with anti-actin antibodies. F, Representative
images from confocal microscopy showing internalization of cell surface GFP-CXCR4 after treatment with SDF-1/CXCR4 (25 ng/ml, 37uC, 30 min) in
the presence of anti-GFP antibodies. The HeLa cells were either treated with control siRNA or depleted of Grk3 or Grk6 using specific siRNA. G, HeLa
cells expressing GFP-WT CXCR4 were transfected with scrambled or siRNAs specific to Grk6, and exposed to SDF-1/CXCL12 (25 ng/ml) for the
indicated time intervals. Cell lysates were separated by SDS-PAGE and analyzed by Western blotting using specific antibodies to phosphorylated pErk
1/2; membranes were re-probed with antibodies to total Erk 1/2 for loading controls.
doi:10.1371/journal.pone.0008102.g005
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pathway is altered in primary cells from a WHIM patient carrying
a 15-residue C-terminal CXCR4 truncation and in cells
transduced with this mutant receptor [31]. Additionally, it was
previously proposed that b-Arrestin 2 contributes to altered
signaling by WHIM-mutant CXCR4 receptor [31,33]. However,
these earlier studies emphasized the enhanced/prolonged signal-
ing by the mutant receptor and its prolonged association with b-
Arrestin 2 in comparison with the WT receptor. Our experiments
disclose the absence of physical interaction between Grk6 to the
activated mutant receptor, a substantial delay in recruitment of b-
Arrestin 2 to the activated mutant receptor, and a delay in
receptor internalization, trafficking and Erk1/2 activation induced
by the ligand. Thus, our results explain the abnormally prolonged
ligand-induced WHIM receptor signaling and impaired receptor
desensitization reported previously [31] on the basis of a combined
effect of WT and WHIM CXCR4 molecules rather than a unique
dysfunction of the mutant receptor.
Grk6-null mice display markedly reduced neutrophil mobiliza-
tion from the bone marrow to the peripheral blood in response to
G-CSF in spite of having normal hematopoiesis. Thus, Grk6
deficiency in mice reflects some of the characteristically defective
neutrophil mobilization of patients with WHIM [19,20]. In vitro
studies with cells from Grk6-null mice showed that splenocytes
have increased receptor ‘‘sensitivity’’ to CXCL12/SDF-1 as
assessed by GTPase activity [33], and bone marrow-derived
neutrophils display increased chemotactic responses to
CXCRL12/SDF-1. WHIM leukocytes also have enhanced
responses to CXCL12/SDF-1 [30,31], much like Grk6-null
neutrophils from the mice. Thus, previous observations support
a role for Grk6 as a regulator of CXCR4 function and a mediator
of receptor dysfunction in WHIM. However, one important
distinction between WHIM patients and Grk6-null mice is that the
mice did not show a difference in blood neutrophil levels
compared to WT mice, suggesting that Grk6 alone does not
control neutrophil release from the bone marrow. Interestingly, a
WHIM patient expressing WT CXCR4 was reported to have
reduced expression of Grk3, suggesting that Grk3 deficiency alone
may be responsible for CXCR4 dysfunction [32]. Our results
suggesting that Grk3 and Grk6 may bind to CXCR4 in different
locations are consistent with the possibility that functional defects
in each of these kinases may be associated with CXCR4
dysfunction and disease. Previously, Grk3 was reported to bind
to CXCR4, but the sites were not further defined [44]. Other
studies have disclosed that the cytoplasmic loops or the tail in
different G protein-coupled receptors can bind different Grks, but
these regions are not conserved between receptors and sequences
conferring Grk-binding activity are currently poorly defined
[46,47]. We now found that CXCR4 lacking 19 carboxy-terminal
residues is defective at recruiting Grk6, but not Grk3.
Grk6 contributes to CXCR4 phosphorylation [44], and
presumably the WHIM-CXCR4 mutant is phosphorylated to a
lower degree than the WT receptor, a result reported by Orsini et
al. [41]. Indeed, various CXCR4 mutants within the carboxy-
terminal tail, including a mutant lacking the terminal 7 residues,
resulted in reduced CXCR4 phosphorylation after activation [41].
An important question is whether a direct relationship exists
between the failure of Grk6 to associate with the WHIM CXCR4
receptor and the observed delay in b-Arrestin 2 recruitment.
Many studies have shown that once phosphorylated, G protein-
coupled receptors bind Arrestins through multiple interactions
[27]. CXCR4 can bind b-Arrestin 2 through the third intracellular
loop and the C-terminal tail [27,48]. In particular, serine clusters
missing from the WHIM mutant receptor may serve to stabilize
CXCR4 interactions with b-Arrestins [27], and contribute to b-
Arrestin 2 regulation of CXCR4 [48].
Previously, b-Arrestin 1 was shown to contribute to CXCR4
internalization and signaling in response to CXCL12/SDF-1 [48],
and to be required for recruitment of the ubiquitin ligase AIP4 and
eventual lysosomal trafficking of the CXCR4 receptor [39]. We
show that the WT and WHIM receptors can both associate with
b-Arrestin 1, and we find no difference in the kinetics of b-Arrestin
1 interaction with WT versus mutant CXCR4 receptors. These
results are consistent with the notion that b-Arrestin 1 and b-
Arrestin 2 have independent functions [42,49], but does not
exclude the possibility that b-Arrestin 1 may play some indirect
role in WHIM-CXCR4 deficiencies. Of note, Cheng et al [48]
observed that b-Arrestin 2 was more dependent on CXCR4
phosphorylation then b-Arrestin 1, an observation supported by
our data showing that a receptor that lacks an interaction with
Grk6 also shows aberrant b-Arrestin 2 recruitment. It is possible
that b-Arrestin 2, once it is recruited to the active CXCR4 [31,48]
may indirectly regulate the phosphorylation of b-Arrestin 1
through the downstream mediators phospho-Erk 1/2 [50], and
by this mechanism modulate the recruitment of clathrin and/or
the ubiquitin ligase AIP4 [39,51]. Noteworthy, CXCR4 sorting to
lysosomes is mediated through ubiquitination of lysine residues
included in the ‘‘degradation motif’’ of CXCR4, which spans
residues 324–333 [51], a region that is preserved in the WHIM
334-mutant receptor.
Several studies have reported the formation of CXCR4 dimers
or heterodimers [31,52–54]. It is unclear how dimerization may
influence the receptor’s ability to bind ligand and signal. In the
case of WHIM patient cells, where both a WT and mutant form
exist, it is possible that extended signaling could result from either
individual receptor signaling, or alternatively from a single
signaling unit comprising heterodimeric WT and mutant CXCR4.
Further work will be required to distinguish between these two
possibilities. Regardless of whether the functional receptor unit is a
dimer or a monomer, our results clearly show the critical role of
Grk6-CXCR4 receptor interaction for proper receptor function.
Most of our studies were performed in the well-characterized
Hela cells, but many of the results were confirmed in neuroblas-
toma cells and myeloid cells. Nonetheless, it is possible that subtle
differences may exist among different cell types depending on
receptor and effectors expression levels. In conclusion, we present
biochemical evidence for the cause of WHIM disease associated
with mutant CXCR4. In addition, our findings provide further
insight into the complex interactions that mediate CXCR4
signaling.
Materials and Methods
Cells and Cell Culture
HeLa and HEK 293 cells (American Type Culture Collection,
ATCC) were propagated in Dulbecco’s Modified Eagles Medium
(DMEM, Gibco) supplemented with 10% heat-inactivated Fetal
Bovine Serum (FBS, Atlanta Biologicals), glutamine and penicil-
lin/streptomycin (Gibco). Stable cell lines expressing recombinant
CXCR4 were produced by transfecting HeLa cells with an
expression plasmid for GFP-tagged human wild-type (WT) or
mutant CXCR4 using Lipofectamine Reagent (Invitrogen) with
5 mg of DNA/10 cm tissue culture plate (BD Biosciences),
according to the manufacturer’s instructions. The transfected
cells were selected by culture in the presence of G418 (5 mg/ml).
The GFP-expressing cells were sorted by flow cytometry (FACS).
Transient transfections of WT and WHIM CXCR4 plasmids in
HEK 293 and HeLa cells grown in six well tissue culture plates
Grk6 and b-Arrestin2 in WHIM
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(Invitrogen) according to the manufacturer’s protocol. The pre-
myeloid cell line KG1a was a kind gift from Jennifer Lippincott-
Schwartz (NICHD, NIH Bethesda, MD). Using the retrovirus
LZRSpBMN-linker-IRES-eGFP plasmid expressing WT CXCR4
or WHIM CXCR4, KG1a cells were infected with a retrovirus
as described [26], and sorted by FACS for GFP expression.
Reagents
Recombinant human SDF-1/CXCL12 was purchased from
R&D Systems or PeProtech, Inc. The following antibodies were
used: anti-GFP (Covance Research Products MMS-118P), anti-
Grk6 (Abnova 8D4), anti-Grk3 (Abcam ab38294), anti-FLAG
(M2, Sigma). All secondary HRP-conjugated antibodies were from
GE Healthcare. All Dylight conjugated secondary antibodies were
from Pierce. Unless otherwise noted, all other reagents were
purchased from Sigma-Aldrich.
Constructs
Human CXCR4 was cloned into the pPCR-Amp Script vector
(Stratagene) by PCR amplification from peripheral blood of a
healthy adult individual or a WHIM patient diagnosed with the
previously described R334X mutation [22]. After digestion with
XhoIand SacIIenzymes,the insertwasligated intothepEGFP-C1
vector (Clontech) at the BamHI and HindIII sites. Accuracy of all
constructs was verified by sequencing. The pcDNA3 Barr1-FLAG
and pcDNA3 Barr2-FLAG plasmids were a kind gift of Dr. Robert
J. Lefkowitz [55] via the Addgene repository (plasmids 14687 and
14685 respectively) [56]. The retrovirus LZRSpBMN-linker-IRES-
eGFP expressing either WT or WHIMwas constructed by digesting
pEGFP-C1-CXCR4-WT or pEGFP-C1-CXCR4-WHIM with
XhoI and NotI and ligating the purified fragment into the LZRS
vector.
RNA Interference
The siRNAs for Grk3 and Grk6 (Dharmacon) were transfected
individually into cells using Oligofectamine (Invitrogen) following
the manufacturer’s instructions. The cells were assayed 36 h after
transfection.
Immunoprecipitation
HeLa cells were grown to approximately 75% confluency, and
then lysed in 1% (vol/vol) Triton X-100 in 150 mM NaCl,
50 mM Tris-HCl, pH 7.5 at 4uC. The supernatants were
precleared for 1 h at 4uC using GammaBind-plus sepharose (GE
Healthcare) and were then incubated overnight at 4uC with a
primary antibody followed by GammaBind-plus sepharose for 1 h.
The beads were spun down and the supernatants removed. The
beads were then washed in wash buffer (150 mM NaCL, 0.1%
Triton X-100, 50 mM Tris HCl pH 7.5) and run through a 4–
20% gradient gel (NuPage), transferred to nitrocellulose and
immunoblotted with various antibodies.
Immunoblotting
Cells were lysed by using 1% (vol/vol) Triton X-100 in 150 mM
NaCl, 50 mM Tris-HCl, pH 7.5 at 4uC. The cells were
centrifuged at 13,000 rpm for 5 min to remove insoluble material,
and NuPage sample buffer was added to the supernatant. The
samples were separated by SDS-PAGE (10–20% NuPage). The
proteins were then transferred to nitrocellulose membranes.
Membranes were blocked for 1 h in TBS with 5% milk (wt/vol)
and 0.5% Tween 20 or in TBS with 0.5% BSA (wt/vol) and 0.5%
Tween 20 if phospho antibodies were used. Primary antibodies
were added in blocking buffer and incubated at 4uC overnight.
The membranes were washed four times with TBS-T (TBS plus
0.05% Tween 20). The secondary antibody was incubated for 1 h
in blocking buffer. The membranes were then washed again in
TBS-T, and proteins were detected by using SuperSignal West
(Pierce).
Uptake and Transferrin Internalization Assay
HeLa cells were grown on glass coverslips (12 mm) to
approximately 75% confluency. The cells were washed with cold
DMEM, and then incubated with anti-GFP antibody (1 mg/
0.1 ml) and/or Transferrin-Alexa 568 (5 mg/0.1 ml, Invitrogen)
on ice for 1 h. The coverslips were then washed three times with
cold DMEM and then incubated at 37uC with 25 ng/ml SDF1/
CXCL12 for the times indicated. The cells were then washed with
cold PBS and fixed with 4% paraformaldehyde for immunoflu-
orescence staining.
Immunofluorescence
Cells were grown in DMEM supplemented with 10% FBS,
glutamine and penicillin/streptomycin. For immunofluorescence,
Hela cells were subcultured onto round 12 mm diameter
coverslips (Daigger) and grown overnight prior to transfection;
24 to 48 h post-transfection, the cells were fixed with 4%
paraformaldehyde in PBS for 12 min, washed twice in PBS for
5 min each and then incubated with the appropriate primary
antibody in a solution of 0.1% saponin, 0.02% sodium azide and
0.1% Fish Skin Gelatin in PBS for 1 h. The coverslips were then
incubated with the appropriate secondary antibody conjugated to
either DyLight 549 or DyLight 633 (Pierce) diluted in the same
solution used for primary antibodies and incubated for 1 h. The
coverslips were then mounted onto glass slides with Fluoromount
G (Southern Biotech) and sealed with nail polish to be viewed on a
Leica SP2 microscope using a 63X objective.
FACS Analysis
Cells were first washed by using PBS, and harvested by adding
5 mM EDTA in PBS and incubating for 5 min at 37uC. The cells
were then washed twice with PBS containing 3% wt/vol BSA. For
GFP analysis the cells were analyzed directly. Where indicated,
primary antibody was added, and the cells incubated on ice for
1 h. The cells were washed three times with PBS-BSA, and
phycoerythrin-conjugated secondary antibody was added for 1 h.
Finally, the cells were washed and analyzed by using a three-color
FACSCalibur flow cytometer equipped with CELLQUEST PRO
software (Becton Dickinson). The data were analyzed using FlowJo
(Tree Star) software.
Attachment Assay
Huvec cells were plated in a monolayer in 96 well flat bottom
plates and prepared as described [38]. 1610
6 KG1a cells were
labeled for 15 minutes at 37uC with 10 mm CFSE in PBS
(Invitrogen). The cells were washed with warm media and placed
at 37uC for an additional 30 min. The KG1a cells were then
added to the 96 well plate containing the Huvec at 1610
5 cells in
50 ml per well. At the end of incubation, non adherent cells were
removed and adherent KG1a cells counted by measuring
fluorescence emission at 520 nm.
Statistical Analysis
Statistical analysis of group differences was evaluated by
Student’s t test; P values of ,0.05 were considered significant.
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Figure S1 Expression levels of Grk proteins in HeLa cell lines.
HeLa cells stably transduced with GFP-WT CXCR4 or GFP-
WHIM were lysed and analyzed by SDS-PAGE and Western
blotting using the noted Grk antibodies.
Found at: doi:10.1371/journal.pone.0008102.s001 (1.28 MB TIF)
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